Hypera Sa S/Adr (HYPMY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to Ipera Pharma's earnings call for the first quarter of 2025. We have with us Mr. Brenno Oliveira, CEO, and Ramon Sosh's CFO and Investor Relations Director. We'd like to inform you that this event is being recorded. You may watch a recording of this on the company's investor relations website, ri.ibera.com.br. We'd like to inform you that all participants are in listen-only mode during the company's presentation. Then we will begin the questions and answers session when further instructions will be given. Before we continue, I'd just like to underscore that some of the information contained in this call may have projections or statements about future expectations. They are subject to risks, uncertainties that may make them not come to pass or to be substantially different from what was expected. Now, I would like to hand it over to Mr. Breno Oliveira, who will begin the company's presentation. Go ahead, sir. Good morning. Thank you for being here for our earnings call for the first quarter of 2025. I'd like to begin on slide three. Our sell-out grew 7% in the first quarter of 2025. In the institutional market, this represented 21%, and in the retail market, it was 6%. We continued to grow significantly in the non-retail market with a huge market share for one additional quarter. Sell-out in retail grew around 5.8%, which is in line with the operating market. and this is due to the strong performance of patented medication that grew 28%. The first quarter was a bit weaker than expected due to this pre-high, which was lower than expected. We expect to have faster growth in the next quarters due to some important launches for the year, which will contribute to a growth of about 8% in sell-out as we expect for 2025. our s...